|
CNBC'S MOST SHARED
- 'We're in the Middle of a Crash': Black Swan
- The Rising Mountain of Debt May Be the Next Crisis
- Latvian Banker Taking Souls as Collateral
- SEC May Reinstate Rules for Short-Selling Stocks
- Cuddle Parties Heat Up
- Your First Move For Monday July 6th
- The Worst Expected 2010 State Budget Gaps
- Malaysia PM Speaks to CNBC
- NY City Apartment Sales Down More Than 50%
- Alaska Governor Sarah Palin Will Resign
- The Rising Mountain of Debt May Be the Next Crisis
- North Korea Fires 7 Missiles Off East Coast
- Alaska Governor Sarah Palin Will Resign
- For Banks, Wads of Cash and Loads of Trouble
- SEC May Reinstate Rules for Short-Selling Stocks
- For Australian Winemakers, More Turns Out to Be Less
- Earnings Season: A Likely Game-Changer
- Slideshow: Best-Selling Fourth of July Fireworks
- Divisions Dominate as Third Quarter Begins
- Fireworks At Pharma's Market
- Value of Warren Buffett's Annual Gift to Gates Foundation Falls Along With Berkshire's Stock
- Michael Jackson: The Music And The Money
- Five Stock Picks for This Market
- Realities of the New Obama Refis
- Weak Dollar Means Gold at $1,040: Strategist
- Court Ruling Could Mean Trouble for TiVo
- Lance, Please Back Out Of Tour
- TeleMedicine Gets An Apple App Store Facelift
The American Heart Association issued new guidelines for Pfizer's Celebrex, advising doctors the painkiller should only be used as a last resort on patients who have heart disease or a risk of developing it, CNBC's Mike Huckman reported.
Celebrex is a COX-2 inhibitor and it's the only drug in that class still on the market in the U.S. after Merck pulled Vioxx and Pfizer pulled Bextra off pharmacy shelves.
In a prepared statement, Pfizer [PFE
Loading...
()
] told Huckman the AHA's recommendations are "oversimplified" and "not based on robust clinical data … and may further confuse patients."
But the American Heart Association says a recent analysis show that COX-2 drugs increase the risk of having a heart attack by 86%. The drug already has a so-called black box warning label, the FDA's toughest warning of heart risk since 2005.
Dr. Elliott Antman, lead author of the AHA's scientific statement and a professor at Harvard Medical School, makes no bones about Pfizer's Celebrex.
"It is not a safe drug," says Antman. "It is not a drug we should turn to as a first line treatment for management of pain in a patient with heart disease. We're actually recommending that it be the last line of treatment."
Antman said heart disease patients should be instructed to diet and exercise and failing that, to try aspirin first, then Tylenol or Aleve.
The most infamous of the COX-2 class is Vioxx, which was pulled from the market by Merck [MRK
Loading...
()
] in 2004 after it was discovered that the drug raised the risk of heart attacks and strokes.
After Vioxx fears eventually subsided, sales of Celebrex rebounded last year with 2006 sales of $2 billion. Pfizer has said it expects the rebound to continue for the franchise again this year.









